108 related articles for article (PubMed ID: 9883555)
1. The analysis of correlated panel data using a continuous-time Markov model.
Lee EW; Kim MY
Biometrics; 1998 Dec; 54(4):1638-44. PubMed ID: 9883555
[TBL] [Abstract][Full Text] [Related]
2. Tests for treatment group differences in the hazards for survival, before and after the occurrence of an intermediate event.
Bebchuk JD; Betensky RA
Stat Med; 2005 Feb; 24(3):359-78. PubMed ID: 15568187
[TBL] [Abstract][Full Text] [Related]
3. A continuous time version and a generalization of a Markov-recapture model for trapping experiments.
Alpizar-Jara R; Smith CE
Math Biosci; 2008; 214(1-2):11-9. PubMed ID: 18556026
[TBL] [Abstract][Full Text] [Related]
4. Bayesian inference for recurrent events data using time-dependent frailty.
Manda SO; Meyer R
Stat Med; 2005 Apr; 24(8):1263-74. PubMed ID: 15568192
[TBL] [Abstract][Full Text] [Related]
5. Joint analysis of longitudinal data with informative right censoring.
Liu M; Ying Z
Biometrics; 2007 Jun; 63(2):363-71. PubMed ID: 17425632
[TBL] [Abstract][Full Text] [Related]
6. Spatial multistate transitional models for longitudinal event data.
Nathoo FS; Dean CB
Biometrics; 2008 Mar; 64(1):271-9. PubMed ID: 17425639
[TBL] [Abstract][Full Text] [Related]
7. CMV trial enrolling.
Vazquez E
Posit Aware; 1997; 8(4):13. PubMed ID: 11364480
[TBL] [Abstract][Full Text] [Related]
8. Size and power of two-sample tests of repeated measures data.
Dawson JD; Lagakos SW
Biometrics; 1993 Dec; 49(4):1022-32. PubMed ID: 7906957
[TBL] [Abstract][Full Text] [Related]
9. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses.
Healy B; Degruttola V
Biostatistics; 2007 Apr; 8(2):438-52. PubMed ID: 16940036
[TBL] [Abstract][Full Text] [Related]
10. Fomivirsen approved for CMV retinitis.
Roehr B
J Int Assoc Physicians AIDS Care; 1998 Oct; 4(10):14-6. PubMed ID: 11365956
[TBL] [Abstract][Full Text] [Related]
11. Finding a place for cidofovir.
Smart T
GMHC Treat Issues; 1996 Jan; 10(1):5-7. PubMed ID: 11363374
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir implant in the treatment of cytomegalovirus retinitis.
Chang M; Dunn JP
Expert Rev Med Devices; 2005 Jul; 2(4):421-7. PubMed ID: 16293081
[TBL] [Abstract][Full Text] [Related]
13. CMV retinitis trial expanding.
Vazquez E
Posit Aware; 1998; 9(1):16. PubMed ID: 11364995
[TBL] [Abstract][Full Text] [Related]
14. Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis.
Kappel PJ; Charonis AC; Holland GN; Narayanan R; Kulkarni AD; Yu F; Boyer DS; Engstrom RE; Kuppermann BD;
Ophthalmology; 2006 Apr; 113(4):683.e1-8. PubMed ID: 16581428
[TBL] [Abstract][Full Text] [Related]
15. FDA approves cidofovir for treatment of CMV retinitis. Food and Drug Administration.
J Int Assoc Physicians AIDS Care; 1996 Aug; 2(8):30. PubMed ID: 11363758
[TBL] [Abstract][Full Text] [Related]
16. A Markov regression model for nutritive sucking data.
Zhang P; Medoff-Cooper B
Biometrics; 1996 Mar; 52(1):112-24. PubMed ID: 8934588
[TBL] [Abstract][Full Text] [Related]
17. A logistic-bivariate normal model for overdispersed two-state Markov processes.
Cook RJ; Ng ET
Biometrics; 1997 Mar; 53(1):358-64. PubMed ID: 9147600
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir trial is enrolling patients.
AIDS Patient Care STDS; 1997 Aug; 11(4):293-4. PubMed ID: 11361853
[No Abstract] [Full Text] [Related]
19. Nonparametric estimation of stage occupation probabilities in a multistage model with current status data.
Datta S; Sundaram R
Biometrics; 2006 Sep; 62(3):829-37. PubMed ID: 16984326
[TBL] [Abstract][Full Text] [Related]
20. New drug recommended for treatment of CMV retinitis.
Bray JM
STEP Perspect; 1996; 8(1):8. PubMed ID: 11363593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
